Baidu
map

心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

《中国高血压患者血压血脂综合管理的专家共识》要点解读

2022-01-15 华北理工大学研究生学院 中华高血压杂志

高血压

据《中国心血管健康与疾病报告2020》显示,2018年,我国心血管病死亡率仍居首位,且心血管病患病率处于持续上升阶段。而相关研究显示,高血压和高胆固醇血症已经成为我国居民缺血性心脏病死亡最重要的危险因

中文标题：

《中国高血压患者血压血脂综合管理的专家共识》要点解读

发布机构：

华北理工大学研究生学院

发布日期：

2022-01-15

简要介绍：

据《中国心血管健康与疾病报告2020》显示,2018年,我国心血管病死亡率仍居首位,且心血管病患病率处于持续上升阶段。而相关研究显示,高血压和高胆固醇血症已经成为我国居民缺血性心脏病死亡最重要的危险因素。

相关资料下载：
[AttachmentFileName(sort=1, fileName=《中国高血压患者血压血脂综合管理的专家共识》要点解读.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d0b2e1c002389649, title=《中国高血压患者血压血脂综合管理的专家共识》要点解读, enTitle=, guiderFrom=中华高血压杂志, authorId=0, author=, summary=据《中国心血管健康与疾病报告2020》显示,2018年,我国心血管病死亡率仍居首位,且心血管病患病率处于持续上升阶段。而相关研究显示,高血压和高胆固醇血症已经成为我国居民缺血性心脏病死亡最重要的危险因, cover=https://img.medsci.cn/2022321/1647876949415_5579292.jpg, journalId=0, articlesId=null, associationId=2548, associationName=华北理工大学研究生学院, associationIntro=华北理工大学研究生学院, copyright=0, guiderPublishedTime=Sat Jan 15 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">据《中国心血管健康与疾病报告2020》显示,2018年,我国心血管病死亡率仍居首位,且心血管病患病率处于持续上升阶段。而相关研究显示,高血压和高胆固醇血症已经成为我国居民缺血性心脏病死亡最重要的危险因素。</span></p>, tagList=[TagDto(tagId=274, tagName=高血压)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=0, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3740, appHits=425, showAppHits=0, pcHits=585, showPcHits=3307, likes=0, shares=58, comments=5, approvalStatus=1, publishedTime=Tue Mar 22 15:33:00 CST 2022, publishedTimeString=2022-01-15, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Mar 21 23:34:08 CST 2022, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 07:55:10 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=《中国高血压患者血压血脂综合管理的专家共识》要点解读.pdf)])
《中国高血压患者血压血脂综合管理的专家共识》要点解读.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1205146, encodeId=8085120514640, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=789e6399598, createdName=ms9000000876588358, createdTime=Wed Mar 23 09:26:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205136, encodeId=8ea01205136e4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c40a6387446, createdName=ms3000000376140643, createdTime=Wed Mar 23 08:35:47 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205122, encodeId=3ec8120512225, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb6e5437912, createdName=ningjinyao, createdTime=Wed Mar 23 08:25:22 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205118, encodeId=a5a6120511849, content=还是要下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Wed Mar 23 08:14:34 CST 2022, time=2022-03-23, status=1, ipAttribution=)]
    2022-03-23 ms9000000876588358

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1205146, encodeId=8085120514640, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=789e6399598, createdName=ms9000000876588358, createdTime=Wed Mar 23 09:26:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205136, encodeId=8ea01205136e4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c40a6387446, createdName=ms3000000376140643, createdTime=Wed Mar 23 08:35:47 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205122, encodeId=3ec8120512225, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb6e5437912, createdName=ningjinyao, createdTime=Wed Mar 23 08:25:22 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205118, encodeId=a5a6120511849, content=还是要下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Wed Mar 23 08:14:34 CST 2022, time=2022-03-23, status=1, ipAttribution=)]
    2022-03-23 ms3000000376140643

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1205146, encodeId=8085120514640, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=789e6399598, createdName=ms9000000876588358, createdTime=Wed Mar 23 09:26:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205136, encodeId=8ea01205136e4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c40a6387446, createdName=ms3000000376140643, createdTime=Wed Mar 23 08:35:47 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205122, encodeId=3ec8120512225, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb6e5437912, createdName=ningjinyao, createdTime=Wed Mar 23 08:25:22 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205118, encodeId=a5a6120511849, content=还是要下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Wed Mar 23 08:14:34 CST 2022, time=2022-03-23, status=1, ipAttribution=)]
    2022-03-23 ningjinyao

    学到了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1205146, encodeId=8085120514640, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=789e6399598, createdName=ms9000000876588358, createdTime=Wed Mar 23 09:26:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205136, encodeId=8ea01205136e4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c40a6387446, createdName=ms3000000376140643, createdTime=Wed Mar 23 08:35:47 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205122, encodeId=3ec8120512225, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb6e5437912, createdName=ningjinyao, createdTime=Wed Mar 23 08:25:22 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205118, encodeId=a5a6120511849, content=还是要下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Wed Mar 23 08:14:34 CST 2022, time=2022-03-23, status=1, ipAttribution=)]
    2022-03-23 12346c4dm64暂无昵称

    还是要下载

    0

相关指南

FDA工业指南：在多种抗高血压药物的背景下进行高血压药物治疗患者的研究

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2020-03-04

FDA工业指南：开发用于治疗的高血压的固定剂量复方药物产品

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2020-03-12

FDA工业指南：高血压药物适应症中心血管结局相关的声明标签

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2020-03-04

高血压患者药物治疗管理路径专家共识

高血压患者药物治疗管理路径编写委员会 · 2022-01-15

2020年菲律宾高血压管理临床实践指南执行摘要

暂未更新 · 2021-08-03

2021 ABCD/RA指南：成人糖尿病肾病患者高血压的治疗与肾素-血管紧张素-醛固酮系统阻断

英国临床糖尿病专家协会(ABCD,Association of British Clinical Diabetologists) · 2022-01-03

Baidu
map
Baidu
map
Baidu
map